Innovation
Wed, Feb 5, 2025 9:55 AM

Development of Innovative, High Value-Added Oncological Drug Products for Personalized Therapies

he project identified as 2020-1.1.2-PIACI-KFI-2020-00039, conducted by Egis Pharmaceuticals PLC and its consortium partner, the HUN-REN Research Centre for Natural Sciences (TTK), finished on December 31, 2024.
Innovation

Development of Innovative, High Value-Added Oncological Drug Products for Personalized Therapies

he project identified as 2020-1.1.2-PIACI-KFI-2020-00039, conducted by Egis Pharmaceuticals PLC and its consortium partner, the HUN-REN Research Centre for Natural Sciences (TTK), finished on December 31, 2024.
Wed, Feb 5, 2025 9:55 AM
Author:
Wed, Feb 5, 2025 9:55 AM
Author:

 

The 4-year project aimed to develop and market modern, targeted generic anti-cancer drug products to make the most advanced therapies accessible to a broader patient population. The total cost of the project was HUF 1,437 million, with the National Research, Development and Innovation Office providing HUF 798 million in non-refundable support under the "Support for Market-Driven Research and Development and Innovation Projects" call announced in 2020.

During the project, active ingredient and product development included laboratory experiments, synthesis route development, laboratory-scale production, toxicological studies, pilot-scale upscaling and production, and, where relevant, large-scale upscaling and registration. More than 150 researchers, developers, and technicians from Egis participated in the industrial research and experimental development tasks of the project. The HUN-REN TTK Medicinal Chemistry Research Group, operating within the National Drug Research and Development Laboratory, also contributed to the industrial research on active ingredients.

As a result of the project, one drug product has already entered the international market, generating revenue significantly exceeding the grant amount. Additionally, a total of 14 new laboratory or production technologies were created, and one PCT patent application was filed. Through the implementation of the project, Egis Pharmaceuticals PLC can expand its oncology product portfolio, thereby strengthening its market position and international competitiveness.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox